New hope for kids with hemophilia: altuviiio trial aims to tame inhibitors
Disease control
Not yet recruiting
This phase 4 trial tests whether Altuviiio (efanesoctacog alpha) can help children with severe hemophilia A and high-titer inhibitors achieve immune tolerance. Participants also receive Hemlibra (emicizumab) to prevent bleeding. The study involves 15 children under 18 and will tr…
Phase: PHASE4 • Sponsor: Versiti Blood Health • Aim: Disease control
Last updated Jun 26, 2026 15:01 UTC